Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April 1, 2024 – March 31, 2025), recording total revenue of JPY 4.58 trillion (USD 30.6 billion) and core revenue of JPY 4,579.8 billion (USD 30.6 billion). This represents a 2.8% year-over-year (YOY) growth at constant exchange rates (CER). Strong performance from growth and launched products offset the impact of patent expirations, driving both revenue and core operating profit growth.
Product Sales and Segment Performance
Product sales from six treatment areas totaled JPY 2.2 trillion (USD 14.7 billion), up 14.7% YOY.
- Gastroenterology: Revenue increased by 7% YOY, driven by Entyvio (vedolizumab) with sales of JPY 914.1 billion (+8.5%) and Eohilia (budesonide oral suspension) at JPY 5.5 billion (+2501%).
- Rare Diseases: Revenue rose by 5% YOY, led by Takhzyro (lanadelumab) with JPY 223.2 billion in sales (+18.9%), Livtencity (maribavir) with JPY 33.0 billion (+64.5%), and Adzynma (apadamtase alfa) with JPY 7.1 billion (+1516%).
- Plasma-Derived Therapies (PDT): Revenue was up 9% YOY, including immunoglobulins with JPY 757.8 billion (+11.5% YoY) and albumin with JPY 141.4 billion (+1.1%).
- Oncology: Revenue increased by 17% YOY, driven by fruquintinib (co-developed with HUTCHMED) with JPY 48.0 billion (+351%) and Alunbrig (brigatinib) with JPY 36.4 billion (+22.7%).
- Vaccines: Revenue was up 8% YOY, primarily from Qdenga (tetravalent dengue vaccine) with JPY 35.6 billion (+259%).
- Neuroscience: Revenue declined by 14% YOY.
Tariff Policy Impact
Takeda stated that potential risks from recent U.S. and Chinese tariff policies are limited. Approximately 50% of its total revenue is derived from the U.S., with imported goods (mainly from Europe/Japan/Singapore) accounting for 8–10% of U.S. revenue. About 4% of total revenue comes from China, with imports (from the U.S.) representing 12–15% of China revenue.-Fineline Info & Tech
